Skip to main content
Top
Published in: Pituitary 3/2015

01-06-2015

Octreotide LAR treatment of acromegaly in “real life”: long-term outcome at a tertiary care center

Authors: Ana Laura Espinosa-de-los-Monteros, Baldomero Gonzalez, Guadalupe Vargas, Ernesto Sosa, Moises Mercado

Published in: Pituitary | Issue 3/2015

Login to get access

Abstract

Objective

To report our day-to day experience with the long-term use of octreotide LAR in the treatment of acromegaly.

Patients and methods

Patients with acromegaly managed between 2003 and 2012 with octreotide LAR for a median of 27 months (interquartile ranges 12–60) and who had not received radiation therapy or concomitant treatment with cabergoline were retrospectively evaluated. Both primarily treated patients (n = 33) and patients who received octreotide after failed pituitary surgery (adjunctive treatment, n = 124) were included. Full biochemical response was defined as the achievement of a GH <2.5 ng/mL and an IGF-1 <1.2 times the upper limit of normal (× ULN); we also evaluated efficacy using a GH cut off of <1 ng/mL.

Results

Over 60 % of the patients achieved a GH of <2.5 ng/mL. The combined GH (<2.5 ng/mL) and IGF-1 (<1.2 × ULN) target was achieved by 35.5 and 33.6 % of the patients treated primarily and adjunctively, respectively; these figures dropped to 22.6 and 23 % when using a GH target of <1 ng/mL. All patients reported a significant improvement in acromegalic symptoms. Lower pretreatment GH and IGF-1 levels were both associated with a higher probability of achieving the composite biochemical target.

Conclusion

Currently recommended GH and IGF-1 targets are reached by <36 % of patients treated with octreotide LAR in a day-to day practice context. Nevertheless, in most instances a clinical benefit and an improvement in biochemical markers can be clearly documented.
Literature
1.
go back to reference Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE et al (2002) Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 87:4554–4563CrossRefPubMed Bevan JS, Atkin SL, Atkinson AB, Bouloux PM, Hanna F, Harris PE et al (2002) Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. J Clin Endocrinol Metab 87:4554–4563CrossRefPubMed
2.
go back to reference Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A et al (2002) First-line octreotide-LAR therapy induces tumor shrinkage and control hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol 64:342–352CrossRef Colao A, Pivonello R, Rosato F, Tita P, De Menis E, Barreca A et al (2002) First-line octreotide-LAR therapy induces tumor shrinkage and control hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol 64:342–352CrossRef
3.
go back to reference Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S et al (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 88:3090–3098CrossRefPubMed Cozzi R, Attanasio R, Montini M, Pagani G, Lasio G, Lodrini S et al (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 88:3090–3098CrossRefPubMed
4.
go back to reference Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S et al (2006) Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 91:1397–1403CrossRefPubMed Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S et al (2006) Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 91:1397–1403CrossRefPubMed
5.
go back to reference Mercado M, Borges F, Bouterfa H, Chang T, Chervin A, Farral A et al (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol 66:859–868CrossRef Mercado M, Borges F, Bouterfa H, Chang T, Chervin A, Farral A et al (2007) A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol 66:859–868CrossRef
6.
go back to reference Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M (2008) A 12-month, randomized cross-over study on the effects of lanreotide autogel and octreotide long acting repeatable on GH and IGF-1 levels in acromegaly. Clin Endocrinol 68:473–480CrossRef Andries M, Glintborg D, Kvistborg A, Hagen C, Andersen M (2008) A 12-month, randomized cross-over study on the effects of lanreotide autogel and octreotide long acting repeatable on GH and IGF-1 levels in acromegaly. Clin Endocrinol 68:473–480CrossRef
7.
go back to reference Melmed S, Cook D, Schopohl J, Goth M, Lam K, Marek J et al (2010) Rapid and sustained reductions of serum growth hormone and insulin-like growth factor 1 in patients with acromegaly receiving lanreotide autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 13:18–28CrossRefPubMedCentralPubMed Melmed S, Cook D, Schopohl J, Goth M, Lam K, Marek J et al (2010) Rapid and sustained reductions of serum growth hormone and insulin-like growth factor 1 in patients with acromegaly receiving lanreotide autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 13:18–28CrossRefPubMedCentralPubMed
8.
go back to reference Howlett T, Willis D, Walker G, Wass J, Trainer P (2013) UK Acromegaly Register Study Group (UKAR-3): control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clin Endocrinol 79:689–699 Howlett T, Willis D, Walker G, Wass J, Trainer P (2013) UK Acromegaly Register Study Group (UKAR-3): control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clin Endocrinol 79:689–699
9.
go back to reference Mestron A, Webb S, Astorga R, Benito P, Catalá M, Gaztambide S et al (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA). Eur J Endocrinol 151:439–446CrossRefPubMed Mestron A, Webb S, Astorga R, Benito P, Catalá M, Gaztambide S et al (2004) Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA). Eur J Endocrinol 151:439–446CrossRefPubMed
10.
go back to reference Sesmilo G, Gaztambide S, Venegas E, Picó A, Del Pozo C, Blanco C et al (2013) Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA). Pituitary 16:115–121CrossRefPubMed Sesmilo G, Gaztambide S, Venegas E, Picó A, Del Pozo C, Blanco C et al (2013) Changes in acromegaly treatment over four decades in Spain: analysis of the Spanish Acromegaly Registry (REA). Pituitary 16:115–121CrossRefPubMed
11.
go back to reference Bex M, Abs R, T’Sjoen G, Mockel J, Velkeniers B, Muermans K et al (2007) AcroBel-the Belgian registry on acromegaly: a survey of the ‘real-life’ outcome in 418 acromegalic subjects. Eur J Endocrinol 157:399–409CrossRefPubMed Bex M, Abs R, T’Sjoen G, Mockel J, Velkeniers B, Muermans K et al (2007) AcroBel-the Belgian registry on acromegaly: a survey of the ‘real-life’ outcome in 418 acromegalic subjects. Eur J Endocrinol 157:399–409CrossRefPubMed
12.
go back to reference Schöfl C, Franz H, Grussendorf M, Honegger J, Jaursch-Hancke C, Mayr B et al (2012) Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. Eur J Endocrinol 168:39–47CrossRefPubMed Schöfl C, Franz H, Grussendorf M, Honegger J, Jaursch-Hancke C, Mayr B et al (2012) Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register. Eur J Endocrinol 168:39–47CrossRefPubMed
13.
go back to reference Giustina A, Chanson P, Bronstein M, Klibanski A, Lamberts S, Casanueva F et al (2010) A consensus on criteria for cure in acromegaly. J Clin Endocrinol Metab 95:3141–3148CrossRefPubMed Giustina A, Chanson P, Bronstein M, Klibanski A, Lamberts S, Casanueva F et al (2010) A consensus on criteria for cure in acromegaly. J Clin Endocrinol Metab 95:3141–3148CrossRefPubMed
14.
go back to reference Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD (2007) Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to somatostaton analogue. Clin Endocrinol 67:310–315CrossRef Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD (2007) Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to somatostaton analogue. Clin Endocrinol 67:310–315CrossRef
15.
go back to reference Sosa E, Espinosa-de-los-Monteros AL, González B, Vargas G, Mercado M (2008) Tratamiento de la acromegalia con octreótido LAR. Rev Med IMSS 46:205–212 Sosa E, Espinosa-de-los-Monteros AL, González B, Vargas G, Mercado M (2008) Tratamiento de la acromegalia con octreótido LAR. Rev Med IMSS 46:205–212
16.
go back to reference Biermasz NR, van den Oever NC, Frolich M, Arias AM, Smit JW, Romijn JA et al (2003) Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clin Endocrinol 58:288–295CrossRef Biermasz NR, van den Oever NC, Frolich M, Arias AM, Smit JW, Romijn JA et al (2003) Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval. Clin Endocrinol 58:288–295CrossRef
17.
go back to reference Turner HE, Thornton-Jones VA, Wass JA (2004) Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clin Endocrinol 61:224–231CrossRef Turner HE, Thornton-Jones VA, Wass JA (2004) Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clin Endocrinol 61:224–231CrossRef
18.
go back to reference Ramirez C, Vargas G, González B, Grossman A, Rábago J, Sosa E, Espinosa de los Monteros AL, Mercado M (2012) Discontinuation of octreotide LAR after successful treatment of patients with acromegaly: is it worth trying? Eur J Endocrinol 166:21–26CrossRefPubMed Ramirez C, Vargas G, González B, Grossman A, Rábago J, Sosa E, Espinosa de los Monteros AL, Mercado M (2012) Discontinuation of octreotide LAR after successful treatment of patients with acromegaly: is it worth trying? Eur J Endocrinol 166:21–26CrossRefPubMed
Metadata
Title
Octreotide LAR treatment of acromegaly in “real life”: long-term outcome at a tertiary care center
Authors
Ana Laura Espinosa-de-los-Monteros
Baldomero Gonzalez
Guadalupe Vargas
Ernesto Sosa
Moises Mercado
Publication date
01-06-2015
Publisher
Springer US
Published in
Pituitary / Issue 3/2015
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-014-0570-0

Other articles of this Issue 3/2015

Pituitary 3/2015 Go to the issue